FTC Approves Final Order Imposing Strict Limits on Future Mergers by Dialysis Service Provider DaVita, Inc.

Federal Trade Commission (FTC)

WASHINGTON, D.C. — Following a public comment period, the Federal Trade Commission this week approved a final order settling charges that dialysis service provider DaVita, Inc.’s acquisition of the University of Utah Health’s dialysis clinics would reduce competition in vital outpatient dialysis services in the Provo, Utah market.

Under the terms of the final settlement, DaVita is required to divest three Provo-area dialysis clinics to Sanderling Renal Services, Inc. and is prohibited from entering into or enforcing non-compete agreements and other employee restrictions. DaVita is also required to receive prior approval from the FTC before acquiring any new ownership interest in a dialysis clinic anywhere in Utah for a period of ten years.

First announced in October 2021, the complaint alleged that there are only three providers of outpatient dialysis services in the greater Provo, Utah area, and the acquisition would eliminate actual, direct, and substantial competition between dialysis clinics owned by DaVita and dialysis clinics owned by the University of Utah Health, and would tend to create a monopoly.

READ:  Comparing Energy Use Costs Can Help Consumers Save Money on Their Utility Bills

The Commission vote to approve the final order was 4-0.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.